Programmed death ligand-1 expression in adrenocortical carcinoma: An exploratory biomarker study

Journal for ImmunoTherapy of Cancer

Volumn 3, Issue 1, 2015, Pages

  Fay, André P ^a,b   Signoretti, Sabina ^c,d   Callea, Marcella ^c   Tel, Gabriela H ^e   McKay, Rana R ^a,c,d   Song, Jiaxi ^c   Carvo, Ingrid ^c   Lampron, Megan E ^a   Kaymakcalan, Marina D ^a   Poli de Figueiredo, Carlos E ^b   Bellmunt, Joaquim ^a,c,d   Hodi, F S ^a,d,f   Freeman, Gordon J ^a,d   Elfiky, Aymen ^a,c,d   Choueiri, Toni K ^a,c,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e JOSLIN DIABETES CENTER   (United States)

^f Center of Immuno Oncology   (United States)

Author keywords

Adrenocortical carcinoma; Immunotherapy; PD 1 inhibitors; PD L1

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MONONUCLEAR CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INFILTRATING MONONUCLEAR CELL; TUMOR VOLUME;

EID: 84977080787     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-015-0047-3     Document Type: Article

References (44)

1. Third national cancer survey: incidence data. Natl Cancer Inst Monogr. 1975;41:i-x, 1-454..
2. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?. World J Surg 2006, 30(5):872-8. doi:10.1007/s00268-005-0329-x, 10.1007/s00268-005-0329-x, 16680602.
3. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 2008, 113(11):3130-6. doi:10.1002/cncr.23886, 10.1002/cncr.23886, 18973179.
4. Khorram-Manesh A, Ahlman H, Jansson S, Wangberg B, Nilsson O, Jakobsson CE, et al. Adrenocortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-up. World J Surg 1998, 22(6):605-11. discussion 11-2, 10.1007/s002689900442, 9597936.
5. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990, 322(17):1195-201. doi:10.1056/NEJM199004263221705, 10.1056/NEJM199004263221705, 2325710.
6. op den Winkel J, Pfannschmidt J, Muley T, Grunewald C, Dienemann H, Fassnacht M, et al. Metastatic adrenocortical carcinoma: results of 56 pulmonary metastasectomies in 24 patients. Ann Thorac Surg 2011, 92(6):1965-70. doi:10.1016/j.athoracsur.2011.07.088, 10.1016/j.athoracsur.2011.07.088, 22000277.
7. Fay AP, Elfiky A, Telo GH, McKay RR, Kaymakcalan M, Nguyen PL, et al. Adrenocortical carcinoma: the management of metastatic disease. Crit Rev Oncol Hematol. 2014. doi:10.1016/j.critrevonc.2014.05.009.
8. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012, 366(23):2189-97. doi:10.1056/NEJMoa1200966, 10.1056/NEJMoa1200966, 22551107.
9. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the study of adrenal cancer. Cancer 1998, 83(10):2194-200. 10.1002/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.3.CO;2-V, 9827725.
10. Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, et al. Streptozocin and o, p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000, 11(10):1281-7. 10.1023/A:1008377915129, 11106117.
11. Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer 2010, 17(2):445-53. doi:10.1677/ERC-09-0281, 10.1677/ERC-09-0281, 20410174.
12. Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 2009, 94(1):204-12. doi:10.1210/jc.2008-1456, 10.1210/jc.2008-1456, 18854392.
13. De Martino MC, van Koetsveld PM, Feelders RA, Sprij-Mooij D, Waaijers M, Lamberts SW, et al. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. Endocr Relat Cancer 2012, 19(3):351-64. doi:10.1530/ERC-11-0270, 10.1530/ERC-11-0270, 22420007.
14. Carden ESK CP, Jones RL, Alam SM, Johnson FM, Stephens AW, Poondru S, et al. Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors. J Clin Oncol 2010, 28:15s. 2010 (suppl; abstr 2530).
15. Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pollinger A, et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab 2012, 97(10):3495-503. doi:10.1210/jc.2012-1419, 10.1210/jc.2012-1419, 22837187.
16. Jimenez P, Guix M, Milagro NL, Mateos LL, Mendez Vidal MJ, Climent Duran MA, et al. Phase II study of dovitinib in first-line metastatic or nonresectable primary adrenocortical carcinoma (ACC): SOGUG study 2011-03. J Clin Oncol. 2012;30(suppl; abstr TPS4688):2014.
17. O'Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S, et al. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab 2014, 99(4):1291-7. doi:10.1210/jc.2013-2298, 10.1210/jc.2013-2298, 24423320.
18. Lerario AM, Worden FP, Ramm CA, Hasseltine EA, Stadler WM, Else T, et al. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Hormones Cancer 2014, 5(4):232-9. doi:10.1007/s12672-014-0182-1, 10.1007/s12672-014-0182-1, 24849545.
19. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010, 236:219-42. doi:10.1111/j.1600-065X.2010.00923.x, 10.1111/j.1600-065X.2010.00923.x, 20636820.
20. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med 2013, 2(5):662-73. doi:10.1002/cam4.106, 24403232.
21. Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 2007, 13(2 Pt 2):709s-15. doi:10.1158/1078-0432.CCR-06-1868, 10.1158/1078-0432.CCR-06-1868, 17255298.
22. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005, 11(8):2947-53. doi:10.1158/1078-0432.CCR-04-1469, 10.1158/1078-0432.CCR-04-1469, 15837746.
23. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, et al. The European Network for the study of adrenal tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer 2010, 46(4):713-9. doi:10.1016/j.ejca.2009.12.007, 10.1016/j.ejca.2009.12.007, 20044246.
24. Thompson RH, Kwon ED. Significance of B7-H1 overexpression in kidney cancer. Clin Genitourin Cancer 2006, 5(3):206-11. doi:10.3816/CGC.2006.n.038, 10.3816/CGC.2006.n.038, 17239274.
25. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004, 101(49):17174-9. doi:10.1073/pnas.0406351101, 10.1073/pnas.0406351101, 15569934.
26. Boland JM, Kwon ED, Harrington SM, Wampfler JA, Tang H, Yang P, et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer 2013, 14(2):157-63. doi:10.1016/j.cllc.2012.05.006, 10.1016/j.cllc.2012.05.006, 22868219.
27. Mullane SA, Werner L, Callea M, Fay AP, Leow JJ, Choueiri TK, et al. PD-L1 expression in mononuclear cells and not in tumor cells, correlated with prognosis in metastatic urothelial carcinoma. J Clin Oncol 2014, 32(suppl; abstr 4552):5s.
28. Harshman LC, Choueiri TK, Drake C, Stephen Hodi F. Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J 2014, 20(4):272-80. doi:10.1097/PPO.0000000000000055, 10.1097/PPO.0000000000000055, 25098288.
29. Karakousis CP, Rao U, Moore R. Adrenal adenocarcinomas: histologic grading and survival. J Surg Oncol 1985, 29(2):105-11. 10.1002/jso.2930290208, 4079384.
30. Hogan TF, Gilchrist KW, Westring DW, Citrin DL. A clinical and pathological study of adrenocortical carcinoma: therapeutic implications. Cancer 1980, 45(11):2880-3. 10.1002/1097-0142(19800601)45:11<2880::AID-CNCR2820451127>3.0.CO;2-#, 7379017.
31. Assie G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2007, 92(1):148-54. doi:10.1210/jc.2006-0706, 10.1210/jc.2006-0706, 17062775.
32. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008, 371(9614):771-83. doi:10.1016/S0140-6736(08)60241-X, 10.1016/S0140-6736(08)60241-X, 18275997.
33. Willenberg HS, Stratakis CA, Marx C, Ehrhart-Bornstein M, Chrousos GP, Bornstein SR. Aberrant interleukin-1 receptors in a cortisol-secreting adrenal adenoma causing cushing's syndrome. N Engl J Med 1998, 339(1):27-31. doi:10.1056/NEJM199807023390105, 10.1056/NEJM199807023390105, 9647876.
34. Quezada SA, Peggs KS. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer 2013, 108(8):1560-5. doi:10.1038/bjc.2013.117, 10.1038/bjc.2013.117, 23511566.
35. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366(26):2443-54. doi:10.1056/NEJMoa1200690, 10.1056/NEJMoa1200690, 22658127.
36. DC Cho, JA Sosman, M Sznol, MS Gordon, A Hollebecque, O Hamid, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting. J Clin Oncol. 2013;31(suppl; abstr 4505).
37. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369(2):122-33. doi:10.1056/NEJMoa1302369, 10.1056/NEJMoa1302369, 23724867.
38. Bellmunt J, Powles T, Braiteh F, Vogelzang N, Cruz C, Burris H, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in pts with metastatic urothelial bladder cancer (UBC). Ann Oncol 2014, 25(suppl 4):iv280-304. doi:101093/annonc/mdu337.
39. Choueiri TK, Fishman MN, Escudier B, Kim JJ, Kluger H, Stadler WM, et al. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial. J Clin Oncol 2014, 32(suppl; abstr 5012):5s.
40. Choueiri TK. Highlights of the Day III Session - Genitourinary (Nonprostate) Cancer 2014.
41. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010, 116(17):3268-77. doi:10.1182/blood-2010-05-282780, 10.1182/blood-2010-05-282780, 20628145.
42. Hsieh C, Chang A, Brandt D, Guttikonda R, Utset TO, Clark MR. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res 2011, 63(6):865-74. doi:10.1002/acr.20441, 10.1002/acr.20441.
43. Haley KJ, Sunday ME, Wiggs BR, Kozakewich HP, Reilly JJ, Mentzer SJ, et al. Inflammatory cell distribution within and along asthmatic airways. Am J Respir Crit Care Med 1998, 158(2):565-72. doi:10.1164/ajrccm.158.2.9705036, 10.1164/ajrccm.158.2.9705036, 9700136.
44. Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 2014, 25(11):2178-84. doi:10.1093/annonc/mdu445, 10.1093/annonc/mdu445, 25193987.